India's Glenmark grants China's Harbour rights to bispecific mAb for cancer

Indian company Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize GBR 1302 in Greater China, including Hong Kong and Macau, and Taiwan. The deal is Glenmark’s first with a Chinese company.

The companies said Glenmark could receive more than $120 million, including an upfront payment and potential milestones, plus royalties. Harbour will also have the option to manufacture GBR 1302 in its territory...